Cartesian Therapeutics Files 8-K

Ticker: RNAC · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1453687

Cartesian Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCartesian Therapeutics, Inc. (RNAC)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

TL;DR

Cartesian Therapeutics filed an 8-K, mostly financial docs, no big news yet.

AI Summary

On January 13, 2025, Cartesian Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclosures detailed in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Frederick, MD.

Why It Matters

This 8-K filing indicates routine corporate reporting, likely related to financial statements and exhibits, without immediate news of significant events.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any new material risks or events.

Key Players & Entities

  • Cartesian Therapeutics, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • Frederick, MD (location) — Address of principal executive offices
  • January 13, 2025 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing for Cartesian Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 13, 2025.

Where are Cartesian Therapeutics, Inc.'s principal executive offices located?

Cartesian Therapeutics, Inc.'s principal executive offices are located at 7495 New Horizon Way, Frederick, MD 21703.

In which state was Cartesian Therapeutics, Inc. incorporated?

Cartesian Therapeutics, Inc. was incorporated in Delaware.

Does this filing indicate any specific material events or disclosures beyond financial statements and exhibits?

Based on the provided text, this filing primarily concerns financial statements and exhibits, and does not detail any other specific material events or disclosures.

Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-13 07:04:47

Key Financial Figures

  • $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Cartesian Therapeutics, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. Additionally, on January 13, 2025, the Company issued a press release announcing its 2025 strategic priorities. This press release is attached to this Current Report on Form 8-K as Exhibit 99.2. The information in Item 7.01 of this Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1 or 99.2, except as required by law.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Corporate slide presentation of Cartesian Therapeutics, Inc. dated January 2025. 99.2 Press release of Cartesian Therapeutics, Inc. issued on January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.